Targeting EHMT2 reverses EGFR-TKI resistance in NSCLC by epigenetically regulating the PTEN/AKT signaling pathway

Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) resistance is a major obstacle in the treatment of non-small cell lung cancer (NSCLC). Epigenetic alterations have been shown to be involved in NSCLC oncogenesis; however, their function in EGFR-TKI resistance remains uncharacteri...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Lihui, Dong, Xiaoyu, Ren, Yong, Luo, Juanjuan, Liu, Pei, Su, Dongsheng, Yang, Xiaojun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833639/
https://www.ncbi.nlm.nih.gov/pubmed/29374157
http://dx.doi.org/10.1038/s41419-017-0120-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833639/
https://www.ncbi.nlm.nih.gov/pubmed/29374157
http://dx.doi.org/10.1038/s41419-017-0120-6

Ejemplares similares